Martinoni Matteo, Marucci Gianluca, Rubboli Guido, Volpi Lilia, Riguzzi Patrizia, Marliani Federica, Toni Francesco, Naldi Ilaria, Bisulli Francesca, Tinuper Paolo, Michelucci Roberto, Baruzzi Agostino, Giulioni Marco
IRCCS Institute of Neurological Science of Bologna, Division of Neurosurgery, Bellaria Hospital, Bologna, Italy.
Department of Biomedical and NeuroMotor Sciences (DiBiNeM), Section of Pathology "M.Malpighi", Bellaria Hospital, University of Bologna, Bologna, Italy.
Epilepsy Behav. 2015 Apr;45:212-6. doi: 10.1016/j.yebeh.2015.01.022. Epub 2015 Mar 23.
Focal cortical dysplasias (FCDs) represent a common architectural cortical disorder underlying pharmacoresistant focal epilepsy. The recent ILAE classification defines different types of FCDs based on their histopathological features, MRI imaging, and presumed pathogenesis; however, their clinical features and their prognostic significance are still incompletely defined. In addition, the combination of different histopathological abnormalities can represent "unusual" subtypes that can be difficult to classify. The aim of our study was to analyze the incidence and the significance of these "unusual" subtypes of FCDs in drug-resistant mesial temporal lobe epilepsy (MTLE).
We retrospectively analyzed 133 patients consecutively submitted to tailored anteromesial temporal lobe resection for pharmacoresistant MTLE. Seizure onset, seizure duration, age at surgery, and postoperative seizure outcome were evaluated in relation to the different neuropathological groups defined according to the new ILAE classification.
Focal cortical dysplasias were found in 80 out of 133 patients. Six patients were affected by isolated FCD type I, 12 patients by FCD type II, and 44 patients by FCD type III. Furthermore, we found 18 "atypical" cases (20.5% of all FCD cases and 26.6% of FCDs associated with a principal lesion): 10 cases of associated FCD type II-hippocampal sclerosis (HS) and 8 cases associated with FCD II-epilepsy-associated tumors (EATs).
Our results indicate that "unusual" subtypes of FCDs, in particular associated FCD type II, are not uncommon findings, suggesting that they deserve a classification recognition. Similarities in seizure outcome and immunohistochemical and molecular evidences, shared by FCD type II+EATs and EATs, suggest a common pathogenic link. The choice to create a specific unifying class or, on the contrary, to also include "associated FCD type II" in the definition of the new unifying class FCD type III should be further discussed.
局灶性皮质发育不良(FCDs)是药物难治性局灶性癫痫常见的皮质结构紊乱疾病。国际抗癫痫联盟(ILAE)最近的分类根据组织病理学特征、MRI成像及推测的发病机制定义了不同类型的FCDs;然而,其临床特征及预后意义仍未完全明确。此外,不同组织病理学异常的组合可能代表难以分类的“不典型”亚型。我们研究的目的是分析这些“不典型”FCDs亚型在药物难治性内侧颞叶癫痫(MTLE)中的发生率及意义。
我们回顾性分析了133例因药物难治性MTLE而接受定制性前内侧颞叶切除术的患者。根据新的ILAE分类定义不同神经病理学组,评估发作起始、发作持续时间、手术年龄及术后发作结果。
133例患者中80例发现局灶性皮质发育不良。6例为孤立性I型FCD,12例为II型FCD,44例为III型FCD。此外,我们发现18例“非典型”病例(占所有FCD病例的20.5%,占与主要病变相关FCD的26.6%):10例为II型FCD合并海马硬化(HS),8例为II型FCD合并癫痫相关肿瘤(EATs)。
我们的结果表明,FCDs的“不典型”亚型,特别是合并II型FCD并不少见这表明它们值得分类认可。II型FCD + EATs与EATs在发作结果、免疫组化及分子证据方面的相似性提示存在共同的致病联系。关于创建一个特定的统一类别,或者相反,将“合并II型FCD”也纳入新的统一类别III型FCD的定义中,这一选择应进一步讨论。